• Incyte swung to a third-quarter 2026 net loss of $784.8 million.
• Research and development expenses more than tripled year over year to $1.79 billion, primarily due to a $1.23 billion Vega acquisition charge.
• Total net sales rose 14% year over year to $1.32 billion, while Opzelura climbed 36% to $255 million.
• Povorcitinib remains under U.S. regulatory review for hidradenitis suppurativa, with potential approval and launch anticipated in the first quarter of 2027.
• FY26 total net sales guidance increased to $5.21 billion–$5.3 billion to reflect continued strong portfolio performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290700BIZWIRE_USPR_____20261029_BW846124) on October 29, 2026, and is solely responsible for the information contained therein.